Format

Send to

Choose Destination
J Lipid Res. 2015 Jun;56(6):1222-33. doi: 10.1194/jlr.D058487. Epub 2015 Apr 12.

A validated LC-MS/MS assay for quantification of 24(S)-hydroxycholesterol in plasma and cerebrospinal fluid.

Author information

1
Diabetic Cardiovascular Disease Center, Washington University School of Medicine, St. Louis, MO 63110.
2
Program in Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892.
3
Therapeutics for Rare and Neglected Diseases National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.
4
Nursing Department, National Institutes of Health, Bethesda, MD 20892.
5
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850.

Abstract

24(S)-hydroxycholesterol [24(S)-HC] is a cholesterol metabolite that is formed almost exclusively in the brain. The concentrations of 24(S)-HC in cerebrospinal fluid (CSF) and/or plasma might be a sensitive marker of altered cholesterol metabolism in the CNS. A highly sensitive 2D-LC-MS/MS assay was developed for the quantification of 24(S)-HC in human plasma and CSF. In the development of an assay for 24(S)-HC in CSF, significant nonspecific binding of 24(S)-HC was observed and resolved with the addition of 2.5% 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) into CSF samples. The sample preparation consists of liquid-liquid extraction with methyl-tert-butyl ether and derivatization with nicotinic acid. Good linearity was observed in a range from 1 to 200 ng/ml and from 0.025 to 5 ng/ml, for plasma and CSF, respectively. Acceptable precision and accuracy were obtained for concentrations over the calibration curve ranges. Stability of 24(S)-HC was reported under a variety of storage conditions. This method has been successfully applied to support a National Institutes of Health-sponsored clinical trial of HP-β-CD in Niemann-Pick type C1 patients, in which 24(S)-HC is used as a pharmacodynamic biomarker.

KEYWORDS:

2-hydroxypropyl-β-cyclodextrin; Niemann-Pick C1 disease; two-dimensional liquid chromatography-tandem mass spectrometry; validation

PMID:
25866316
PMCID:
PMC4442878
DOI:
10.1194/jlr.D058487
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center